We concluded that ALA treatment may suppress hepatic NLRP3 inflammasome activation, consequently alleviating NAFLD and excess hepatic lipid accumulation in HFD/STZ‐induced T2DM rats. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.